Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism
The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
CONTEXT: Patients with hypertension have a high prevalence of concurrent metabolic abnormalities, including obesity, dyslipidemia, and hyperglycemia. Clustering of these cardiovascular risk factors, defined as metabolic syndrome, causes a more pronounced target organ damage. Aldosterone excess has been found to be associated with glucose disorders and may contribute to cardiovascular damage. OBJECTIVE: The aim of our study was to assess the prevalence and the characteristics of the metabolic syndrome in a group of patients with hypertension due to primary aldosteronism compared with patients with essential hypertension. METHODS: The National Cholesterol Education Program Adult Treatment Panel III definition of the metabolic syndrome was used. Eighty-five patients with primary aldosteronism and 381 patients with essential hypertension were studied. Most patients were not receiving antihypertensive therapy during the investigation. RESULTS: Blood glucose and systolic blood pressure were higher (P < 0.05 and P < 0.01, respectively) and duration of hypertension was longer (P < 0.05) in primary aldosteronism than in essential hypertension. The prevalence of metabolic syndrome was higher in primary aldosteronism than in essential hypertension (41.1% vs. 29.6%; P < 0.05). Distribution of single components of the metabolic syndrome other than hypertension showed a higher prevalence of hyperglycemia in primary aldosteronism than in essential hypertension (27.0% vs. 15.2%; P < 0.05). CONCLUSIONS: Our findings confirm a negative effect of aldosterone excess on glucose metabolism and suggest that the recently reported higher rates of cardiovascular events in primary aldosteronism than in essential hypertension might be due to increased prevalence of the metabolic syndrome in the former condition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Primary aldosteronism (PA) is associated with increased risk for dysglycemia.”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [6]
In the citing paper
“Higher plasma mineralocorticoid levels may be associated with IR (, ).”
From Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management (2017) · cites this paper as [166]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547
The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension
Kaplan, N. M. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.7.1514 · Cited by 1,516
Hyperinsulinemia. A link between hypertension obesity and glucose intolerance.
Modan, M., Halkin, H., Almog, S., Lusky, A., Eshkol, A., Shefi, M., Shitrit, A., & Fuchs, Z. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111776 · Cited by 1,465
Pathophysiology of insulin resistance in human disease
Reaven, G. M. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.3.473 · Cited by 1,226
(1999) · Clinical and Experimental Hypertension · doi:10.3109/10641969909061028 · Cited by 1,209
Triggering and amplifying pathways of regulation of insulin secretion by glucose.
Henquin, J. C. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1751 · Cited by 1,201
Mulatero (2004) · doi:10.1210/jc.2003-031337 · Cited by 961
Self-citationLaaksonen, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf145 · Cited by 916
Ferrannini, E., Natali, A., Bell, P., Cavallo-Perin, P., Lalic, N., & Mingrone, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119628 · Cited by 898
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1992) · Medical Science Symposia Series · doi:10.1007/978-94-011-2700-4_10 · Cited by 865
Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension
Calhoun, D. A., Nishizaka, M. K., Zaman, M. A., Thakkar, R. B., & Weissmann, P. (2002) · Hypertension · doi:10.1161/01.hyp.0000040261.30455.b6 · Cited by 763
(1999) · Blood Pressure · doi:10.1080/08037059943973313 · Cited by 720
Primary Aldosteronism and Hypertensive Disease
Mosso, L., Carvajal, C., González, A., Barraza, A., Avila, F., Montero, J., Huete, A., Gederlini, A., & Fardella, C. E. (2003) · Hypertension · doi:10.1161/01.hyp.0000079505.25750.11 · Cited by 488
Drug Effects on Aldosterone/Plasma Renin Activity Ratio in Primary Aldosteronism
Mulatero, P., Rabbia, F., Milan, A., Paglieri, C., Morello, F., Chiandussi, L., & Veglio, F. (2002) · Hypertension · doi:10.1161/01.hyp.0000038478.59760.41 · Cited by 392
Self-citationPrognostic value of the metabolic syndrome in essential hypertension
Schillaci, G., Pirro, M., Vaudo, G., Gemelli, F., Marchesi, S., Porcellati, C., & Mannarino, E. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.12.049 · Cited by 352
Vascular function, insulin resistance and fatty acids
Steinberg, H., & Baron, A. (2002) · Diabetologia · doi:10.1007/s00125-002-0800-2 · Cited by 341
Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism
Lithell, H. O. L. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.203 · Cited by 339
Hypertension, the Potassium Ion and Impaired Carbohydrate Tolerance
Conn, J. W. (1965) · New England Journal of Medicine · doi:10.1056/nejm196511182732106 · Cited by 329
Changes in Left Ventricular Anatomy and Function in Hypertension and Primary Aldosteronism
Rossi, G. P., Sacchetto, A., Visentin, P., Canali, C., Graniero, G. R., Palatini, P., & Pessina, A. C. (1996) · Hypertension · doi:10.1161/01.hyp.27.5.1039 · Cited by 328
Devereux, R. B., & Alderman, M. H. (1993) · Circulation · doi:10.1161/01.cir.88.4.1444 · Cited by 298
The renin-angiotensin-aldosterone system, glucose metabolism and diabetes
Giacchetti, G., Sechi, L. A., Rilli, S., & Carey, R. M. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.02.003 · Cited by 267
Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics
Haffner, S. M., Fong, D., Hazuda, H. P., Pugh, J. A., & Patterson, J. K. (1988) · Metabolism · doi:10.1016/0026-0495(88)90133-3 · Cited by 254
Effects of Antihypertensive Therapy on Serum Lipids
Kasiske, B. L., Ma, J. Z., Kalil, R. S. N., & Louis, T. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-2-199501150-00010 · Cited by 252
Reaven, G. M. (1994) · PubMed · Cited by 241
Magill, S. B., Raff, H., Shaker, J. L., Brickner, R. C., Knechtges, T. E., Kehoe, M. E., & Findling, J. W. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7282 · Cited by 236
Pathophysiological effects of aldosterone in cardiovascular tissues
Rocha, R., & Stier, C. T. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00432-5 · Cited by 212
Prevalence of the metabolic syndrome in drug‐treated hypertensive patients and control subjects
Rantala, A. O., Kauma, H., Lilja, M., Savolainen, M. J., Reunanen, A., & Kesäniemi, Y. A. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00429.x · Cited by 211
Magill, S. B. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.3.1066 · Cited by 195
Metabolic syndrome and target organ damage in untreated essential hypertensives
Cuspidi, C., Meani, S., Fusi, V., Severgnini, B., Valerio, C., Catini, E., Leonetti, G., Magrini, F., & Zanchetti, A. (2004) · Journal of Hypertension · doi:10.1097/00004872-200410000-00023 · Cited by 188
Further evaluation of saline infusion for the diagnosis of primary aldosteronism.
Holland, O. B., Brown, H., Kuhnert, L., Fairchild, C., Risk, M., & Gomez-Sanchez, C. E. (1984) · Hypertension · doi:10.1161/01.hyp.6.5.717 · Cited by 178
Chinali, M., Devereux, R. B., Howard, B. V., Roman, M. J., Bella, J. N., Liu, J. E., Resnick, H. E., Lee, E. T., Best, L. G., & de Simone, G. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.09.009 · Cited by 157
Diagnosis of primary aldosteronism: from screening to subtype differentiation
Mulatero, P., Dluhy, R. G., Giacchetti, G., Boscaro, M., Veglio, F., & Stewart, P. M. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.02.007 · Cited by 155
Self-citationAldosterone as a cardiovascular risk factor
Rossi, G. P., Boscaro, M., Ronconi, V., & Funder, J. W. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.02.010 · Cited by 148
Human Endothelium: Target for Aldosterone
Oberleithner, H., Ludwig, T. E., Riethmüller, C., Hillebrand, U., Albermann, L., Schäfer, C., Shahin, V., & Schillers, H. (2004) · Hypertension · doi:10.1161/01.hyp.0000123572.45556.a5 · Cited by 139
LEONCINI, G., RATTO, E., VIAZZI, F., VACCARO, V., PARODI, D., PARODI, A., FALQUI, V., TOMOLILLO, C., DEFERRARI, G., & PONTREMOLI, R. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01468.x · Cited by 130
Mulatero, P., Veglio, F., Pilon, C., Rabbia, F., Zocchi, C., Limone, P. P., Boscaro, M., Sonino, N., & Fallo, F. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4946 · Cited by 129
Self-citationAldosterone-induced cardiac damage: focus on blood pressure independent effects
Schmidt, B. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)03199-0 · Cited by 114
Aldosterone as a Cardiovascular Risk Factor
Yoo, S. J. (2007) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2007.22.1.8 · Cited by 112
Metabolic syndrome and endothelial dysfunction
Fornoni, A., & Raij, L. R. (2005) · Current Hypertension Reports · doi:10.1007/s11906-005-0080-6 · Cited by 107
Left Ventricular Hypertrophy Precedes Other Target-Organ Damage in Primary Aldosteronism
Shigematsu, Y., Hamada, M., Okayama, H., Hara, Y., Hayashi, Y., Kodama, K., Kohara, K., & Hiwada, K. (1997) · Hypertension · doi:10.1161/01.hyp.29.3.723 · Cited by 102
The effect of aldosterone on glucose metabolism
Corry, D. B., & Tuck, M. L. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0065-2 · Cited by 90
Evidence for an Increased Rate of Cardiovascular Events in Patients With Primary Aldosteronism
Milliez, P., Giererd, X., Plouin, P., Blacher, J., Safar, M. E., & Jd, M. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.08.031 · Cited by 80
Bo, S., Gentile, L., Ciccone, G., Baldi, C., Benini, L., Dusio, F., Lucia, C., Forastiere, G., Nuti, C., Cassader, M., et al. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.561 · Cited by 76
DELLAMEA, P., LUPIA, M., BANDOLIN, V, GUZZON, S., SONINO, N., VETTOR, R., & FALLO, F. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.08.029 · Cited by 76
Self-citationMancia, G., Volpe, R., Boros, S., Ilardi, M., & Giannattasio, C. (2003) · Journal of Hypertension · doi:10.1097/00004872-200401000-00012 · Cited by 75
Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment
Šindelka, G., Widimsky, J., Jr., Haas, T., Prázný, M., Hilgertová, J., & Škrha, J. (2012) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0032-1329211 · Cited by 74
Insulin Resistance in Secondary Hypertension
Shamiss, A., Carroll, J., & Rosenthal, T. (1992) · American Journal of Hypertension · doi:10.1093/ajh/5.1.26 · Cited by 72
Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy.
Plavinik, F. L., Rodrigues, C. I., Zanella, M. T., & Ribeiro, A. B. (1992) · Hypertension · doi:10.1161/01.hyp.19.2_suppl.ii26 · Cited by 62
Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism?
Shimamoto, K., Shiiki, M., Ise, T., Miyazaki, Y., Higashiura, K., Fukuoka, M., Hirata, A., Masuda, A., Nakagawa, M., & Iimura, O. (1994) · PubMed · Cited by 50
Lim, H. S., Lip, G. Y. H., & Blann, A. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0616 · Cited by 42
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism
MULATERO, P. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)00766-0 · Cited by 41
Self-citationMultiple Metabolic Syndrome: Aspects of Genetic Epidemiology and Molecular Genetics
Kesäniemi, Y. A., Lilja, M., Kervinen, K., & Rantala, A. O. (1992) · Annals of Medicine · doi:10.3109/07853899209166996 · Cited by 23
METABOLIC SYNDROME AND TARGET ORGAN DAMAGE IN UNTREATED ESSENTIAL HYPERTENSIVES
Meani, S., Cuspidi, C., Fusi, V., Severgnini, B., Valerio, C., Catini, E., Leonetti, G., Magrini, F., & Zanchetti, A. (2004) · Journal of Hypertension · doi:10.1097/00004872-200406002-00047 · Cited by 16
Cited by
Monticone, S., D'Ascenzo, F., Moretti, C., Williams, T. A., Veglio, F., Gaita, F., & Mulatero, P. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30319-4 · Cited by 1,072
Self-citationPrevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice
Monticone, S., Burrello, J., Tizzani, D., Bertello, C., Viola, A., Buffolo, F., Gabetti, L., Mengozzi, G., Williams, T. A., Rabbia, F., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.052 · Cited by 882
Self-citationPrimary aldosteronism: renaissance of a syndrome
Young, W. F. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02775.x · Cited by 680
Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., & Vaidya, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30367-4 · Cited by 677
Sowers, J. R., Whaley-Connell, A., & Epstein, M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00005 · Cited by 351
Metadata
- Authors
- Fallo, F., Veglio, F., Bertello, C., Sonino, N., Della Mea, P., Ermani, M., Rabbia, F., Federspil, G., & Mulatero, P.
- Affiliations
- University of Padua (IT)
- University of Turin (IT)
- Corresponding author
- Fallo, Francesco
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-02
- Volume
- 91
- Issue
- 2
- Pages
- 454-459
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2099583783
- Semantic Scholar
- 5b2795dc0ee3d66f4f0cf0367b9210dd5492663a
- Cited by
- 372
- References
- 61
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 12 · 2023: 16 · 2022: 14 · 2021: 16 · 2020: 22 · 2019: 26 · 2018: 23 · 2017: 23 · 2016: 18 · 2015: 17 · 2014: 17 · 2013: 22 · 2012: 23
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Università degli Studi di Padova
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, metabolic syndrome, essential hypertension, hyperglycemia, aldosterone excess, glucose metabolism, cardiovascular risk, dyslipidemia, obesity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Blood Glucose, Blood Pressure, Female, Humans, Hyperaldosteronism, Hypertension, Cholesterol, HDL, Male, Middle Aged, Prospective Studies, Triglycerides, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.